Molly Hoult

Founder and CEO

Molly has 30 years of commercial experience in biopharma, diagnostics, medical devices, digital therapeutics, and life science tools.  She works collaboratively with clients, combining their internal knowledge and data with new market insights and perspective, to develop effective and actionable commercial strategies.

Previously as a leader at Eversana Management Consulting and at Fletcher Spaght, Molly completed hundreds of strategy consulting projects.  She is expert at identifying the core strategic issues, identifying the relevant information, and deploying robust methodologies to collect and analyze data to answer key strategic questions. Her scientific training forms the foundation of her nuanced understanding of technical challenges and clinical needs.  Moreover, working on a wide range of healthcare products has given her a sophisticated understanding of critical success factors and how they vary by sector and market which has resulted in the mental agility to develop new business models and work with new product categories.  With a dedication to quality, Molly applies intellectual rigor to assess the right path for each client rather than relying on “cookie cutter” approaches.

A decade in industry has made Molly a more pragmatic and effective consultant; she held senior management roles in marketing and business development at Blue Heron (DNA synthesis services now part of Origene), Xcyte Therapeutics (ex vivo T cell activation), ZymoGenetics (protein therapeutics informed by bioinformatics and genomics, now part of BMS), and NeoPath (cervical cancer diagnostics, now part of BD Diagnostics).  In these industry roles, Molly launched three products, closed more than 100 transactions (acquisitions, licenses, and partnerships), and raised both private and public capital.

Molly’s investment and transaction experience also includes a decade at Fletcher Spaght Venture Capital, where she evaluated hundreds of prospective investments, syndicated and managed two as a Board Director and Advisor.  As a consultant, Molly provided diligence for private equity and corporate investors, as well as advice on partnering, fundraising and exit strategies to dozens of young companies.

Molly graduated as an Arjay Miller Scholar (top 10%) with an M.B.A. from Stanford Graduate School of Business. She also holds a B.A. in biology with honors and a minor in environmental sciences from Dartmouth College.